Schumacher, David
Liehn, Elisa A.
Nilcham, Pakhwan
Mayan, David Castaño
Rattanasopa, Chutima
Anand, Kaviya
Crespo-Avilan, Gustavo E.
Hernandez-Resendiz, Sauri
Singaraja, Roshni R.
Cook, Stuart A.
Hausenloy, Derek J.
Funding for this research was provided by:
Ministry of Health, Singapore Ministry of Health’s National Medical Research (NMRC/CSA-SI/0011/2017)
Article History
Received: 11 May 2021
Accepted: 24 September 2021
First Online: 19 October 2021
Competing interests
: SAC is an inventor on the patent applications: WO/2017/103108 (TREATMENT OF FIBROSIS), WO/2018/109174 (IL-11 ANTIBODIES), WO/2018/109170 (IL-11RA ANTIBODIES). S.A.C. is a shareholder of Enleofen Bio PTE LTD. The remaining authors (DS, EAL PN, DCM, CR, KA, GEC, SHR, RRS and DJH) declare no competing interests.